✦ LIBER ✦

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211

✍ Scribed by Byrd, J C; Peterson, B; Piro, L; Saven, A; Vardiman, J W; Larson, R A; Schiffer, C

Book ID: 110055308
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 107 KB
Volume: 17
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2402752

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of single-agent bortezomi

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

✍ Stefan Faderl; Kanti Rai; John Gribben; John C. Byrd; Ian W. Flinn; Susan O'Brie 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views

Randomized phase 2 study of fludarabine

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

✍ Byrd, J. C. 📂 Article 📅 2002 🏛 American Society of Hematology 🌐 English ⚖ 192 KB

Treatment of refractory chronic lymphocy

Treatment of refractory chronic lymphocytic leukemia with prednimustine: A phase II study using strict response criteria

✍ David R. Gandara; Christopher B. George; Curt A. Ries; Maria M. Koretz; Jerry P. 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 388 KB

Twenty-one patients with refractory chronic lymphocytic leukemia (CLL) were entered into this Northern California Oncology Group (NCOG) study of prednimustine, an ester of chlorambucil and prednisolone. All patients had active disease and were refractory to standard alkylating agent chemotherapy. Tr

Early Results of a Phase II Study Adding

Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (Cll)

✍ M.L. Sorror; B. Storer; B.M. Sandmaier; T. Chauncey; B. Bruno; N.N.S. Andersen; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 93 KB

5.30 Preliminary Results from a Phase I/

5.30 Preliminary Results from a Phase I/II Study of Fludarabine (F), Rituximab (R), and Lenalidomide (L) in Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

✍ Ian W. Flinn; Ines M. Macias-Perez; Patrick S. Tucker; R. Seth Cooper; Habib H. 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 95 KB

Rituximab in Allogeneic Hematopoietic St

Rituximab in Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia With Fludarabine + Total Body Irradiation Conditioning: Results of a Phase II Prospective Multicenter Study (Itac 02-02)

✍ M. Michallet; M. Sobh; S. Morisset; M. Mohty; G. Socie; R. Tabrizi; N. Milpied; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 70 KB